Physician profile
Christopher Jordan Mallard
NPI 1134533102
$47,006.68
in general payments reported to CMS, 2019-2025
34 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,754 · 2020: $1,412 · 2021: $7,786 · 2022: $1,490 · 2023: $9,847 · 2024: $4,120 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $10K · Travel and Lodging: $9,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,832.07 |
| Consulting Fee | $10,180.00 |
| Travel and Lodging | $9,552.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15,601.70 | 2019-2025 | Proclaim, Eterna, Infinity |
| Si-Bone, INC. | $13,337.02 | 2023-2025 | |
| Zavation Medical Products, LLC | $6,000.00 | 2021 | |
| Spinal Simplicity, LLC | $2,295.04 | 2020-2025 | Ha Minuteman G3-R, Patriot Si |
| Nevro Corp. | $1,725.80 | 2019-2024 | Senza |
| Boston Scientific Corporation | $1,383.80 | 2019-2025 | Intracept, General - Pain Management, Clinical Trial Product |
| Relievant Medsystems, INC. | $988.88 | 2020-2023 | Intracept |
| Painteq LLC | $975.46 | 2022-2023 | Painteq |
| Depuy Synthes Sales INC. | $959.02 | 2023-2025 | Trialtis, Confidence Spinal Cement System, Synflate |
| Medical Device Business Services, INC. | $944.06 | 2024-2025 | Skyline |
| Globus Medical, INC. | $886.41 | 2025 | Vyrsa V1, Senza |
| Medtronic, INC. | $584.75 | 2022-2024 | Synchromedii |
| Medtronic USA, INC. | $396.93 | 2019 | |
| Spr Therapeutics, INC | $139.80 | 2025 | Sprint Pns System |
| Tersera Therapeutics LLC | $137.89 | 2019-2024 | Prialt |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $127.21 | 2021-2024 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $120.56 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $42.91 | 2021 | |
| Collegium Pharmaceutical, INC. | $39.18 | 2021 | |
| Merit Medical Systems INC | $38.75 | 2022 | |
| Fidia Pharma USA INC. | $38.06 | 2019-2020 | |
| Forte Bio-Pharma LLC | $29.55 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $26.05 | 2019 | |
| Biodelivery Sciences International, INC. | $25.05 | 2020 | |
| Grt US Holding, INC. | $24.10 | 2021 | |
| Bioventus LLC | $22.37 | 2019 | |
| Ethicon US, LLC | $18.80 | 2025 | Stratafix |
| Allergan, INC. | $15.14 | 2020 | |
| Hikma Pharmaceuticals USA | $14.49 | 2021 | |
| Abbvie INC. | $14.01 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.93 | 2021 | |
| Zyla Life Sciences, INC. | $13.55 | 2019 | |
| Pfizer INC. | $13.21 | 2021 | |
| Radius Health, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mallard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.